Aequus Pharmaceuticals Inc. (CVE:AQS – Get Free Report)’s stock price reached a new 52-week low during mid-day trading on Wednesday . The stock traded as low as C$0.01 and last traded at C$0.01, with a volume of 10000 shares. The stock had previously closed at C$0.01.
Aequus Pharmaceuticals Stock Performance
The company has a current ratio of 0.07, a quick ratio of 0.46 and a debt-to-equity ratio of 138.88. The firm has a market cap of C$1.33 million, a PE ratio of -1.00 and a beta of -0.02. The business has a fifty day moving average price of C$0.01 and a 200 day moving average price of C$0.02.
About Aequus Pharmaceuticals
Aequus Pharmaceuticals Inc operates as a specialty pharmaceutical company in Canada. The company markets ZIMED PF, a preservative-free bimatoprost ophthalmic solution. It also develops a range of prescription-free dry eye products under the OPTASE name; and REV-0100 for the treatment of stargardt disease.
Featured Stories
- Five stocks we like better than Aequus Pharmaceuticals
- Special Purpose Acquisition Company (SPAC) What You Need to Know
- Driving Forward: Lucid’s Growing Sales and Gravity SUV’s Impact
- Insider Trading – What You Need to Know
- Why Amazon’s Next Earnings Could Trigger a Stock Breakout
- How is Compound Interest Calculated?
- With This Kind of Data, The Fed Isn’t Cutting Rates This Year
Receive News & Ratings for Aequus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aequus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
